-
Immunicum is advancing a novel immuno-oncology approach to treat solid tumors through its lead program ilixadencel
Immunicum is listed on NASDAQ Stockholm under the ticker IMMU
Tweets by @Immunicum
Tweets by ImmunicumPress Releases
Immunicum AB (publ) Announces Positive Phase II MERECA Topline Results Including Complete Tumor Responses in Metastatic Renal Cell Carcinoma Patients
29 Aug 2019Immunicum AB (publ) Interim Report January – June 2019
20 Aug 2019Immunicum AB (publ) Announces New Issuance Date for Interim Report April – June 2019 and Corporate Update Event
28 Jun 2019
Latest Corporate presentation
Quarterly Report Presentation & Business Strategy video - 20 Aug 2019 Corporate presentation August 2019News
-
Video Interviews on MERECA Phase II Data
4 Sep 2019 -
MERECA Q&A – Swedish
3 Sep 2019 -
MERECA Q&A – English
30 Aug 2019 -
Information on MERECA
29 Aug 2019 -
Quarterly Report Presentation & Business Strategy video & slides
21 Aug 2019
About us
Developing innovative cancer immunotherapies
Immunicum is advancing a novel cell-based approach to target solid tumors.
Learn more
